



**PHARMACY AND THERAPEUTICS COMMITTEE
ACA/Exchange MEETING MINUTES
March 6, 2025**

Attendance: Microsoft Teams Meeting
 Gary Bledsoe, Staff/Clinical Pharmacist; Dr. Kevin Caputo, Magellan Health; Connie Chan, Staff/Clinical Pharmacist; Edgar Chou, Jefferson Health; Jerry Crawford, Staff/Clinical Pharmacist; Sahani de Silva, Pharmacy Student Intern; Dr. Neal Demp, Community Behavior Health; Dawson Do, Pharmacy Student Intern; Danielle Dolores, Director of Pharmacy; George E. Downs, Dean Emeritus and Professor, St. Joseph's University; Leah Finken, Clinical Programs Pharmacist; Sharon Ford, Staff/Clinical Pharmacist; Paul Goebel, Assistant Director Pharmacy, Jefferson Enterprise; Yelena Hedrick, Staff/Clinical Pharmacist; Samantha Jackson, Clinical Pharmacist; Ruth John, Pharmacy Resident; Lawrence Jones, Retired Executive Director, Pennsylvania Society of Health-System Pharmacists (PSHP); Kaylei Koerwitz, Manager Pharmacy Operations and Clinical Programs; Dr. Tania Kolev, Medical Director; Hannah McCaffrey, Manager Pharmacy Regulations & Implementation; Brandi Mahler, Supervisor Pharmacy Technicians; Lisa Murray, Staff/Clinical Pharmacist; Kateryna Olchowecky, Clinical Programs Pharmacist; Maryana Prokopets, Staff/Clinical Pharmacist; Sara Sadiq, Staff/Clinical Pharmacist; Julie Samuel, Clinical Programs Pharmacist; Heather Scheckner, Clinical Pharmacist, Jefferson Health; Mike Smikovecus, Staff/Clinical Pharmacist; Robert Spencer, Staff/Clinical Pharmacist; Shelley Staffa, Clinical Pharmacist; Justin Steffan, Pharmacy Resident; Brian Swift, Enterprise Vice President/Chief Pharmacy Officer, Jefferson Health; Jessica Tran, Staff/Clinical Pharmacist; Fallan Vaisberg, Formulary Pharmacist; Ramesh Vangala, Vice President of Pharmacy Operations; Jeanine Zubrzycki, Staff/Clinical Pharmacist

Excused: Demian Elder, Medical Director; Merleen Harris-Williams, Medical Director; Sanjiv Raj, Associate VP Customer Engagement; Dr. Chris Squillaro, Medical Director, Magellan Behavioral Health

Minutes taken by: Joana Iverson

I. Administrative Update

TOPIC	DISCUSSION	ACTIONS	RESPONSIBLE PARTY	RESOLVED/PENDING
<i>Minutes Review/Approval</i>	<i>D. Dolores presented the minutes from the November 2024 meeting to the Committee for review.</i>	<i>The Committee approved the minutes from our last meeting as presented.</i>	<i>D. Dolores</i>	<i>Resolved</i>
<i>Administrative Update</i>	2024 Year in Review <ul style="list-style-type: none"> • <i>Prior Authorizations</i> • <i>Top 10 Drugs and Drug Classes</i> • <i>NCQA QM/UM 5 Timeliness</i> 		<i>D. Dolores</i>	<i>Informational</i>

II. Prior Authorization Review/Updates

TOPIC	DISCUSSION	ACTIONS	RESPONSIBLE PARTY	RESOLVED/PENDING
<p>Prior Authorization Criteria Review – No Clinical Changes</p>	<p>The Committee reviewed the Prior Authorization Criteria. The Committee approved as presented.</p> <ul style="list-style-type: none"> • <i>Albendazole</i> • <i>Brimonidine topical gel</i> • <i>Chorionic gonadatropin (hCG)</i> • <i>Continuous Glucose Monitors</i> • <i>Cresemba</i> • <i>Dalfampridine</i> • <i>Fuzeon</i> • <i>Growth Hormones (somatropin agents)</i> • <i>Jublia</i> • <i>Nexium (esomeprazole) Packets</i> • <i>Nuedexta</i> • <i>Omnipod</i> • <i>Phenoxybenzamine</i> • <i>Rukobia</i> • <i>Sapropterin</i> • <i>Synarel</i> • <i>Wakefulness Promoting Agents</i> 	<p>The Committee approved as presented.</p>	<p><i>F. Vaisberg</i></p>	<p><i>Resolved</i></p>
<p>CVS Caremark Criteria</p>	<p>The Committee reviewed the CVS Caremark Criteria.</p> <ul style="list-style-type: none"> • <i>Aranesp</i> • <i>Cystadane (betaine powder)</i> • <i>Cystagon</i> • <i>Deflazacort</i> • <i>Dificid</i> • <i>Dimethyl Fumarate</i> • <i>Eligard</i> • <i>Fingolimod - Gilenya - Tascenso</i> • <i>Isotretinoins</i> • <i>Kevzara</i> • <i>Lupron Depot-PED</i> • <i>Methyltestosterone</i> • <i>Mircera</i> • <i>Nitisinone</i> • <i>Orenitram</i> • <i>Orilissa</i> 	<p>The Committee approved as presented.</p>	<p><i>F. Vaisberg</i></p>	<p><i>Resolved</i></p>

TOPIC	DISCUSSION	ACTIONS	RESPONSIBLE PARTY	RESOLVED/ PENDING
	<ul style="list-style-type: none"> • <i>Plegridy</i> • <i>Prolia</i> • <i>Retacrit-Procrit-Epogen</i> • <i>SCIG (Subcutaneous immune globulin)</i> • <i>Simponi</i> • <i>Sucraid</i> • <i>Teriflunomide</i> • <i>Tobramycin inhalation</i> • <i>Tremfya</i> • <i>Tymlos</i> • <i>Tyvaso</i> • <i>Voriconazole VFEND</i> • <i>Zoledronic Acid (Reclast)</i> • <i>Zometa (zoledronic acid)</i> 			
<p>Prior Authorization Criteria Review</p>	<p><i>The Committee reviewed the Prior Authorization Criteria. The Committee approved as presented.</i></p> <ul style="list-style-type: none"> • <i>Botulinum Toxins</i> • <i>GLP-1 Agonists</i> <ul style="list-style-type: none"> ○ <i>Ozempic</i> ○ <i>Trulicity</i> • <i>Otezla</i> • <i>Pegfilgrastim Agents</i> • <i>Sirturo</i> • <i>Oral Oncology Agents (Applies to all formulary and non-formulary oncology agents)</i> • <i>Posaconazole</i> • <i>Pyrimethamine</i> • <i>Cerdelga</i> • <i>Octreotide products</i> • <i>Signifor</i> • <i>Somavert</i> • <i>Vigabatrin</i> • <i>Haegarda</i> • <i>Rezdiffra</i> • <i>CFTR Modulators</i> • <i>Otezla</i> • <i>Vemlidy</i> • <i>Non-Formulary Exception</i> • <i>Adalimumab agents</i> • <i>Taltz</i> 	<p><i>The Committee approved as presented.</i></p>	<p><i>F. Vaisberg G. Bledsoe M. Prokopets M. Smikovecus R. John S. Staffa S. Ford Y. Hedrick S. Jackson</i></p>	<p><i>Resolved</i></p>

TOPIC	DISCUSSION	ACTIONS	RESPONSIBLE PARTY	RESOLVED/PENDING
	<ul style="list-style-type: none"> • <i>Increlex</i> • <i>Zepbound</i> 			

III. Drug Formulary Review/Update

<p>Formulary Additions</p>	<p>The Committee reviewed the Formulary Additions and approved as presented.</p> <ul style="list-style-type: none"> • <i>Abilify Maintena 300 mg prsyrr - T3, QL 1/28 days</i> • <i>Abilify Maintena 400 mg prsyrr - T3, QL 1/28 days</i> • <i>Adalimumab-adaz 20 mg/0.2mL soln prsyrr - T5, PA</i> • <i>Augtyro 160 mg cap - T5, PA</i> • <i>Dabigatran etexilate mesylate cap - T2, QL 60/30 days</i> • <i>Esomeprazole magnesium packet - T2, PA, QL 30/30 days</i> • <i>Estradiol 0.75 mg/1.25 gm (0.06%) gel - T4</i> • <i>Evrysdi 5 mg tab - T5, PA, QL 30/30 days</i> • <i>Feirza 1.5/30 1.5-30 mg-mcg tab - T0</i> • <i>Fulphila 6 mg/0.6mL soln prsyrr - T5, PA</i> • <i>Invega Hafyera 1092 mg/3.5mL susp prsyrr - T3, QL 3.5/180 days</i> • <i>Invega Hafyera 1560 mg/5mL susp prsyrr - T3, QL 5/180 days</i> • <i>Invega Sustenna 117 mg/0.75mL susp prsyrr - T3, QL 0.75/28 days</i> • <i>Invega Sustenna 156 mg/mL susp prsyrr - T3, QL 1/28 days</i> • <i>Invega Sustenna 234 mg/1.5mL susp prsyrr - T3, QL 1.5/28 days</i> • <i>Invega Sustenna 39 mg/0.25mL susp prsyrr - T3, QL 0.25/28 days</i> • <i>Invega Sustenna 78 mg/0.5mL susp prsyrr - T3, QL 0.5/28 days</i> • <i>Invega Trinza 273 mg/0.88mL susp prsyrr - T3, QL 0.88/28 days</i> • <i>Invega Trinza 410 mg/1.32mL susp prsyrr - T3, QL 1.32/28 days</i> • <i>Invega Trinza 546 mg/1.75mL susp prsyrr - T3, QL 1.75/84 days</i> • <i>Invega Trinza 819 mg/2.63mL susp prsyrr - T3, QL 2.63/84 days</i> 	<p>The Committee reviewed the Formulary Additions and approved as presented.</p>	<p><i>F. Vaisberg</i></p>	<p><i>Resolved</i></p>
-----------------------------------	---	--	---------------------------	------------------------


	<ul style="list-style-type: none"> • <i>Ivabradine hcl tab - T4, QL 60/30 days</i> • <i>Lisdexamfetamine dimesylate cap - T2, QL 30/30 days</i> • <i>Lumakras 240 mg tab - T5, PA</i> • <i>Mesna 400 mg tab - T5</i> • <i>Minzoya 0.1-20 mg-mcg(21) tab - T0</i> • <i>Omnipod 5 DexG7G6 pods gen 5 - T3, PA</i> • <i>Valtya 1/50 1-50 mg-mcg tab - T0</i> 			
Non-Formulary Quantity Limit Additions	<p><i>The Committee reviewed the Non-Formulary Quantity Limit Additions and approved as presented.</i></p> <ul style="list-style-type: none"> • <i>Miebo 1.338 gm/ml solution - NF, QL 3 mL/30 days</i> • <i>Reyvow 50 mg tab - NF, QL 4/30 days</i> • <i>Reyvow 100 mg tab - NF, QL 8/30 days</i> • <i>Zavzpret 10 mg/act solution - NF, QL 8/30 days</i> 	<i>The Committee reviewed the Non-Formulary Quantity Limit Additions and approved as presented.</i>	<i>F. Vaisberg</i>	<i>Resolved</i>
Tier Changes	<p><i>The Committee reviewed the Tier Changes. The Committee approved as presented.</i></p> <p><i>Moved to T4, Non-Preferred Drugs</i></p> <ul style="list-style-type: none"> • <i>Alyq 20 mg tab</i> • <i>Carglumic acid 200 mg tab sol</i> • <i>Cinacalcet hcl 30 mg tab</i> • <i>Cinacalcet hcl 60 mg tab</i> • <i>Cinacalcet hcl 90 mg tab</i> • <i>Cystagon 150 mg cap</i> • <i>Cystagon 50 mg cap</i> • <i>Miglustat 100 mg cap</i> • <i>Mitoxantrone hcl 20 mg/10mL conc</i> • <i>Mitoxantrone hcl 25 mg/12.5mL conc</i> • <i>Mitoxantrone hcl 30 mg/15mL conc</i> • <i>Penicillamine 250 mg tab</i> • <i>Prolia 60 mg/mL soln prsyr</i> • <i>Tadalafil (pah) 20 mg tab</i> • <i>Tasimelteon 20 mg cap</i> • <i>Tolvaptan 15 mg tab</i> • <i>Tolvaptan 30 mg tab</i> • <i>Yargesa 100 mg cap</i> • <i>Zoledronic acid 4 mg/5mL conc</i> • <i>Zoledronic acid 5 mg/100mL solution</i> 	<i>The Committee approved the Tier Changes as presented.</i>	<i>F. Vaisberg</i>	<i>Resolved</i>
IV. New Drug Review	<p><i>(Presented in New Drug Review for Medicaid.) The following new products were reviewed and will be kept as non-formulary:</i></p> <ul style="list-style-type: none"> • <i>Romvimza (vimseltinib) Capsules</i> 	<i>The Committee approved the New Drug Review as presented and recommended.</i>	<i>R. John</i>	<i>Resolved</i>

	<ul style="list-style-type: none"> • <i>Penmenvy (meningococcal groups A, B, C, W, and Y vaccine) Lyophilized Powder for Injection</i> • <i>Vimkunya (chikungunya vaccine, recombinant) Injection</i> • <i>Merilog (insulin aspart-szjj) Injection</i> • <i>Ospomyv (denosumab-dssb) Injection</i> • <i>Xbryk (denosumab-dssb) Injection</i> • <i>Gomekli (mirdametinib) Capsules and Tablets for Oral Suspension</i> • <i>Emblaveo (avibactam and aztreonam) Lyophilized Powder for Injection</i> • <i>Onapgo (apomorphine hydrochloride) Infusion Device - formerly SPN-830</i> • <i>Journavx (suzetrigine) Tablets - formerly VX-548</i> • <i>Symbravo (meloxicam and rizatriptan) Tablets - formerly AXS-07</i> • <i>Aytozma (tocilizumab-anoh) Injection</i> • <i>Grafapex (treosulfan) Lyophilized Powder for Injection</i> • <i>Datroway (datopotamab deruxtecan-dlnk) Lyophilized Powder for Injection</i> • <i>Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) Subcutaneous Injection</i> • <i>Alhemo (concizumab-mtci) Injection</i> • <i>Alyftrek (deutivacaftor, tezacaftor and vanzacaftor)</i> • <i>Tryngolza (olezarsen) Injection</i> • <i>Symvess (acellular tissue engineered vessel-tyod) for Surgical Vascular Implantation</i> • <i>Ryoncil (remestemcel-L-rknd) Cell Suspension for Intravenous Infusion</i> • <i>Ensacove (ensartinib) Capsules</i> • <i>Steqeyma (ustekinumab-stba) Injection</i> • <i>Crenessity (crinecerfont) Capsules and Oral Solution</i> • <i>Unloxcyt (cosibelimab-ipdl) Injection</i> • <i>Bizengri (zenocutuzumab-zbco) Injection</i> • <i>Yesintek (ustekinumab-kfce) Injection</i> • <i>Attruby (acoramidis) Tablets</i> • <i>Imkeldi (imatinib mesylate) Oral Solution</i> • <i>Rapiblyk (landiolol) Lyophilized Powder for Injection</i> • <i>Ziihera (zanidatamab-hrii) Lyophilized Powder for Injection</i> 			
--	--	--	--	--

	<ul style="list-style-type: none"> • <i>Revuforj (revumenib) Tablets</i> • <i>Kebilidi (eladocagene exuparvovec-tneq) Suspension for Intraputaminial Infusion – formerly Upstaza</i> • <i>Aucatzyl (obecabtagene autoleucel) Suspension for Intravenous Infusion</i> • <i>Danziten (nilotinib tartrate) Tablets</i> • <i>Emrosi (minocycline hydrochloride) Extended-Release Capsule formerly DFD-29</i> • <i>Orlynvah (sulopenem etzadroxil and probenecid) Tablets</i> 			
--	--	--	--	--

V. Adjournment

There being no further business to discuss, the meeting was adjourned. Next meeting is to be held May 2025.



3/24/2025

Danielle Dolores, Director of Pharmacy Services

Date